The enriched pathways play a pivotal role in the occurrence and development of endometrial cancer, thus representing attractive and promising therapeutic targets, such as PARP inhibitors, and mTOR inhibitors [7, 20]. This evidence concerns the gene MTOR and endometrial cancer.